Search results
Theravance Biopharma First Quarter 2024 Earnings: Beats Expectations
Simply Wall St. via Yahoo Finance· 3 days agoEarnings per share (EPS) also surpassed analyst estimates by 5.0%. Looking ahead, revenue is...
US Patent Office ARP Affirms the Use of Means-Plus-Function Limitations to Claim Antibodies | JD...
JD Supra· 3 hours agoIn the recent decision Ex parte Chamberlain, Appeal 22-1944 (Xencor), the United States Patent and Trademark Office’s new Appeals Review Panel provided clarity regarding its stance on means-plus-function ...
Insider Sale: Cencora Inc (COR) CEO Steven Collis Sells 10,755 Shares
GuruFocus.com via Yahoo Finance· 2 days agoThe company operates through various segments, including Pharmaceutical Distribution and Strategic...
Ironwood shares hold as Wells Fargo maintains price target By Investing.com
Investing.com· 2 days agoOn Wednesday, Wells Fargo (NYSE:WFC) maintained its Overweight rating and $14.00 price target on...
Guest opinion: Don't break the life-sciences industry - San Francisco Business Times
The Business Journals· 1 day agoThe last discovery of a new class of antimicrobials that reached the market was in 1987. If...
Cantor Fitzgerald sets price target on Skye Bioscience shares By Investing.com
Investing.com· 1 day agoOn Thursday, Cantor Fitzgerald began coverage on Skye Bioscience Inc. (NASDAQ:SKYE), assigning an...
3 Undervalued Stocks With Strong Upside That Analysts Absolutely Love | Investing.com
Investing.com· 11 hours agoStocks Analysis by Investing.com (Jesse Cohen) covering: Nasdaq 100, Adobe Systems Incorporated,...
The Highest Paid CEOs of 2023
The Wall Street Journal· 4 days ago(The company posted a 3% return in 2021.) Ride-sharing giant Uber Technologies...Among the 25 worst-performing companies in the Journal analysis, nearly...
Insider Sale: CEO & President Reshma Kewalramani Sells 15,202 Sh
Guru Focus· 5 days agoOn May 20, 2024, Reshma Kewalramani, CEO & President of Vertex Pharmaceuticals Inc (VRTX, Financial), executed a sale of 15,202 shares of the company, according to the SEC ...
New data from the Phase 3 NEURO-TTRansform study evaluating WAINUA™ (eplontersen) to be presented at...
WKRN Nashville· 1 day agoIonis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will present new subgroup analyses from Ionis and AstraZeneca's Phase 3 NEURO-TTRansform study of WAINUA ...
